WHO Lists First Bundibugyo Virus Diagnostic Test for Congo-Uganda Outbreak

ByDental Info

The World Health Organization added the first diagnostic test for Bundibugyo virus to its emergency-use list on July 2, expanding confirmation capacity during an outbreak in the Democratic Republic of the Congo and Uganda.

The World Health Organization added the first diagnostic test for Bundibugyo virus to its Emergency Use Listing on July 2, 2026, giving health authorities a new tool to confirm infections during an outbreak in the Democratic Republic of the Congo and Uganda.

The test is designed to identify the virus’s genetic material in blood samples. WHO said the listing can support rapid and accurate confirmation, an important step for surveillance and containment when health officials are tracking a cross-border outbreak.

What the listing changes

An Emergency Use Listing is an authorization for use in an urgent public-health setting. It does not make the diagnostic test a vaccine or a treatment, and the source packet does not identify the manufacturer or product name.

The practical change is diagnostic capacity. Faster confirmation can help officials distinguish suspected infections from cases that require other explanations, while supporting the surveillance, contact tracing and infection-control measures WHO has emphasized in its outbreak guidance.

WHO’s action came after the agency declared a public health emergency of international concern over the outbreak on May 17, 2026. The outbreak is centered in the Democratic Republic of the Congo, with cases also reported in Uganda. The listing was issued as a global emergency-health action, but it does not establish that the virus is spreading globally.

No specifically licensed vaccine or treatment

WHO says there is no vaccine specifically licensed for Bundibugyo virus disease and no specific therapeutic for the illness. In guidance issued May 28, the agency discussed possible cross-protection from Ervebo, a licensed Ebola virus vaccine, while emphasizing surveillance, contact tracing, infection control and community engagement.

That distinction matters. The newly listed product is a diagnostic test intended to detect viral genetic material in blood; it is not an immunization and does not treat an infected patient. The approved material does not say that Ervebo has been specifically licensed for Bundibugyo virus disease or that the vaccine has ended the outbreak.

WHO reports additional U.S. case

In a July situation update, WHO reported that a second U.S. citizen, identified as a humanitarian worker, tested positive in the Democratic Republic of the Congo. The worker was medically evacuated to Frankfurt. The update means at least two U.S. citizens had tested positive by that point, according to the source summary.

The packet does not provide a total case count, and it does not establish how many infections occurred in each country. Those omissions limit what can be concluded about the outbreak’s size or trajectory.

What happens next

WHO assessed the risk to the rest of Africa and globally as low in its July update. That is the agency’s current assessment, not a declaration that the risk is zero. WHO also called for continued surveillance, cross-border coordination and preparedness.

The newly available diagnostic test is therefore one part of a broader response rather than a standalone solution. Health authorities still need to identify suspected cases, confirm infections, trace contacts and maintain infection-control practices. WHO’s guidance also highlights the importance of engaging affected communities.

Further epidemiological information could change the risk assessment. For now, the July 2 listing gives responders in the affected countries a first WHO-listed diagnostic option for detecting Bundibugyo virus, while the outbreak response continues without a specifically licensed vaccine or treatment for the disease.

Sources

Related